Abstract:Isocitrate dehydrogenase (IDH) inhibitors are transforming the treatment of patients with non-enhancing grade 2 IDH-mutant gliomas. Uncertainty remains on the utility of IDH-inhibitors in high-grade IDH-mutant glioma patients that had prior therapies and have progressive disease. From October 2020 to December 2023, we identified high-grade IDH1-mutant patients treated with off-label ivosidenib, a mutant IDH1 inhibitor. We report their clinical and imaging characteristics. In our cohort (n=18), the patient age range was 29-68 years with male predominance (n=11). Diagnoses included astrocytoma grades 3 (n=9) or 4 (n=2), and oligodendroglioma grade 3 (n=7). The median number of progressions prior to ivosidenib initiation was 2 (range 1-7). Fifteen patients had prior surgical resection, three had biopsy. Prior treatment exposures included radiation therapy (n=15), temozolomide (n=18), lomustine (n=5), bevacizumab (n=3), etoposide (n=1), optune (n=1) and a clinical trial (n=1). Mean time from diagnosis to ivosidenib treatment was 9.6 years (95% CI, 6.7 to 16.4 years). Karnofsky performance-status score upon initiation was 80 (n=6) or 90 (n=12). Thirteen patients had >1 cm enhancing disease, five had non-enhancing disease. Ivosidenib was initiated due to enhancing disease progression (n=11), non-enhancing disease progression (n=4), a combination of both (n=2) or temozolomide intolerance (n=1). Best radiographic responses per RANO criteria were partial response (n=2), minor response (n=3), stable disease (n=7), and progressive disease (n=6). Nine patients continue ivosidenib without disease progression, with a median treatment duration of 27.5 months (95% CI, 18.0 to 33.0 months). All had FLAIR stabilization/improvement and 45% (n=4) had improved enhancing disease. Nine patients discontinued ivosidenib due to progression, with a median treatment duration of 7 months (95% CI, 3 to 9 months). These data suggest that treatment with an IDH inhibitor can provide disease control for some high-grade IDH-mutant glioma patients who had prior therapies and progressive disease. Future studies are needed to investigate this patients population.

Sensorimotor and Cognitive Performance of Schizophrenic Inpatients Treated with Haloperidol, Flupenthixol, or Clozapine

The Role of Mutant IDH Inhibitors in the Treatment of Glioma

Dominantly inherited, non-coding microsatellite expansion disorders.

Treatment of IDH-mutant glioma in the INDIGO era

Isocitrate Dehydrogenase Inhibitors in Glioma: From Bench to Bedside

Systematic Review of Epigenetic Therapies for Treatment of IDH-mutant Glioma

A hypnoanalytic exploration of the psychopathology of blushing and erythrophobia.

Therapies for IDH-Mutant Gliomas

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment

Targeting IDH-Mutant Glioma

Ibuprofen inhibits granulocyte responses to inflammatory mediators

To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma

Multidisciplinary Management of Isocitrate Dehydrogenase–Mutated Gliomas in a Contemporary Molecularly Defined Era

Treatment Options for IDH-Mutant Malignant Gliomas

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications

Innv-37. Real-World Outcomes Among High Grade Idh1-Mutant Glioma Patients Treated With An Idh Inhibitor

Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma

Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.

Exth-08. Ivosidenib Therapy For Idh-Mutant Who Grade 4 Astrocytoma

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma